Top Page
Atlas Arteria
(OTC:ALX)
Atlas Arteria (ALX) vs. iShares MSCI Australia ETF (EWA)
Atlas Arteria Business Overview & Revenue Model
Atlas Arteria Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 145.00M | 134.00M | 118.24M | 100.52M | 104.56M |
| Gross Profit | ||||
| 138.70M | 16.40M | 116.00K | -9.05M | -13.55M |
| EBIT | ||||
| -8.10M | -5.10M | -23.35M | -24.91M | -30.69M |
| EBITDA | ||||
| 106.30M | 425.70M | 63.07M | -11.95M | -93.68M |
| Net Income Common Stockholders | ||||
| 335.90M | 323.50M | 266.96M | 163.70M | -99.21M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 351.50M | 305.30M | 275.90M | 229.39M | 260.34M |
| Total Assets | ||||
| 8.26B | 8.04B | 8.33B | 5.22B | 5.27B |
| Total Debt | ||||
| 1.85B | 1.72B | 1.74B | 1.65B | 1.55B |
| Net Debt | ||||
| 1.50B | 1.42B | 1.46B | 1.42B | 1.29B |
| Total Liabilities | ||||
| 1.95B | 1.81B | 1.84B | 1.72B | 1.63B |
| Stockholders Equity | ||||
| 3.34B | 6.24B | 6.49B | 3.50B | 3.63B |
| Cash Flow | Free Cash Flow | |||
| 92.10M | 712.80M | 473.14M | 38.56M | 24.00M |
| Operating Cash Flow | ||||
| 93.20M | 713.60M | 473.50M | 40.03M | 25.44M |
| Investing Cash Flow | ||||
| 633.00M | 631.70M | -3.01B | 304.05M | -976.67M |
| Financing Cash Flow | ||||
| -683.80M | -673.00M | 2.58B | -374.71M | -232.73M |
Atlas Arteria Technical Analysis
Atlas Arteria Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$7.76B | 28.19 | 4.45% | 7.48% | 8.88% | 7.47% | |
66 Neutral | $4.51B | 12.22 | 5.40% | 3.63% | 4.14% | -12.01% | |
| €4.28B | 30.69 | 7.24% | 2.39% | ― | ― | ||
| $3.50B | 12.24 | 9.38% | 4.22% | ― | ― | ||
| $29.13B | 586.79 | 0.68% | 4.52% | ― | ― | ||
78 Outperform | AU$2.00B | 22.97 | 7.48% | 5.82% | 19.38% | 10.66% | |
74 Outperform | AU$887.95M | 17.02 | 5.35% | 4.89% | 22.28% | 50.12% |
Atlas Arteria Corporate Events
Atlas Arteria has announced the appointment of Ms. Elisha Larkin as Joint Company Secretary, effective June 3, 2025. This strategic appointment, alongside Mr. Clayton McCormack, aims to enhance the company’s communication with the ASX, potentially strengthening its governance and operational transparency.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.66 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced the issuance of 759,565 performance rights under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to align employee interests with company performance, potentially enhancing operational efficiency and stakeholder value.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.66 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced a change in the director’s interest, with Hugh Wehby acquiring 654,884 Performance Rights under the company’s Long Term Incentive Plan. This move, approved at the 2025 AGM, reflects the company’s commitment to aligning its leadership’s interests with long-term strategic goals, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.66 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced that its subsidiary APRR has successfully priced €500 million in Eurobonds under its Euro Medium Term Note Programme. The bonds, with a 5.6-year term and a 2.875% coupon, will mature in January 2031, and the proceeds will be used for general corporate purposes. This issuance reflects strong market confidence in APRR and enhances its liquidity position, indicating a positive impact on the company’s financial stability and market standing.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.66 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Diamond Infraco 1 Pty Ltd, on behalf of the IFM Group, has increased its voting power in Atlas Arteria from 29.88% to 32.58%, reflecting a significant change in its substantial holding. This increase in stake could potentially enhance the influence of the IFM Group over Atlas Arteria’s strategic decisions, impacting the company’s operational direction and possibly affecting shareholder dynamics.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.66 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced an amendment to the constitution of Atlas Arteria Limited, following approval by securityholders at the recent Annual General Meeting. This change reflects the company’s ongoing commitment to governance and operational efficiency, potentially impacting its strategic positioning and stakeholder relations.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.66 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria International Limited has amended its Bye-Laws following approval from securityholders at the recent Annual General Meeting. This amendment reflects the company’s ongoing commitment to governance and operational adjustments, potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.66 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced the results of resolutions from its Annual General Meetings for Atlas Arteria Limited and Atlas Arteria International Limited, which were decided by a poll. This announcement reflects the company’s ongoing commitment to transparency and governance, potentially impacting its operational strategies and stakeholder relations.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.66 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria held its 2025 Annual General Meetings, where the Chair and CEO addressed securityholders. The company continues to focus on disciplined management and sustainable practices to enhance its toll road operations across France, Germany, and the United States. This strategic focus aims to strengthen its market position and deliver long-term value to stakeholders.
The most recent analyst rating on (AU:ALX) stock is a Hold with a A$5.55 price target. To see the full list of analyst forecasts on Atlas Arteria stock, see the AU:ALX Stock Forecast page.
Atlas Arteria announced the resignation of Mr. Paul Lynch as Joint Company Secretary, effective May 2, 2025. Mr. Clayton McCormack will continue as the sole Company Secretary, ensuring compliance with ASX communication requirements. This change in company secretarial roles is part of the company’s ongoing governance and operational management, potentially impacting its administrative efficiency and stakeholder communications.
Atlas Arteria announced that S&P Global Ratings downgraded the underlying rating of Toll Road Investors Partnership II, L.P.’s long-term senior unsecured bonds from ‘BB-‘ to ‘B+’, with a negative outlook due to uncertainties surrounding toll increases. Despite the downgrade, there will be no breach or default under TRIP II’s financing documents, and the interest rate on the bonds remains unaffected.
Atlas Arteria reported an increase in both traffic and toll revenue for Q1 2025, with a 1.6% rise in traffic and a 6.1% increase in toll revenue compared to the same period in 2024. This growth was attributed to the rebound in traffic at APRR following previous disruptions, toll increases, and favorable foreign exchange movements. Additionally, the company announced leadership changes, appointing Mr. Luis Tejerina as CEO of the Chicago Skyway and initiating a search for a new CEO at Dulles Greenway, highlighting a strategic focus on strengthening leadership in key areas.
Atlas Arteria has announced the cessation of 277,757 performance rights due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could have implications for stakeholders, as it reflects on the company’s operational targets and performance metrics.
Atlas Arteria announced the issuance and conversion of unquoted equity securities, with a total of 50,047 securities being issued. This move is part of the company’s ongoing financial strategies to enhance its capital structure, potentially impacting its market positioning and offering implications for its stakeholders.
Atlas Arteria has released materials related to its 2025 Annual General Meetings, including a letter from the chairs, AGM notices, and a proxy form. These documents are available on the company’s website. This announcement signifies the company’s ongoing commitment to transparency and stakeholder engagement, potentially impacting its operational strategies and investor relations.
Atlas Arteria has released its 2024 Sustainability Report, highlighting its continued commitment to sustainable operations and community benefits through its toll road projects. The report underscores the company’s strategic focus on reducing environmental impact and enhancing travel efficiency, which is expected to strengthen its market position and provide long-term value to stakeholders.
Atlas Arteria has announced a change in the interests of a substantial holder, State Street Corporation and its subsidiaries, which now hold a 6.72% voting power in the company. This change reflects the company’s ongoing adjustments in its shareholder structure, potentially impacting its governance and strategic decisions.
Atlas Arteria announced a distribution of 20.0 Australian cents per stapled security for the second half of 2024, aligning with previous guidance. This distribution, to be paid by Atlas Arteria International Limited, is an unfranked dividend, with key dates set for trading, record, and payment. This announcement underscores Atlas Arteria’s commitment to delivering consistent returns to its investors, potentially strengthening its market position and investor confidence.
Atlas Arteria has announced a new dividend distribution of AUD 0.20 per security, covering the six-month period ending December 31, 2024. The ex-dividend date is set for March 25, 2025, with a record date of March 26, 2025, and payment scheduled for April 4, 2025. This announcement reflects the company’s ongoing commitment to delivering value to its shareholders and may influence its market positioning by reinforcing investor confidence.